Skip to main content
Equibles
JAGX logo

JAGX · Jaguar Health, Inc.

Track JAGX — free

Use JAGX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.72 -0.01 (-1.49%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements. While management believes this infusion improves our liquidity, it does not fully alleviate the conditions that raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements.”
View the 10-Q filed Aug 19, 2026
Market Cap
$3.78M
Shares
5.17M

JAGX metrics

51 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.73
Market cap
$3.78M

Price action

19 metrics
Price change (1W)
-21.0%
Price change (30D)
-26.9%
Price change (3M)
-77.3%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
148.2%
Beta
—
RSI (14D)
28.8
Price vs SMA 50
-51.1%
Price vs SMA 200
—
Avg volume (3M)
120,447
Relative volume
0.9
Average dollar volume
$171,220

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
5.17M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 15,067.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 736.2%
P / book
0.8
reciprocal yield 130.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
450.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-19

Profitability

9 metrics
Gross margin
82.3%
Operating margin
-93.1%
Trailing 12 months
Net margin
61.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$25.89M
Net income (TTM)
$17.02M
Trailing 12 months
Diluted EPS (TTM)
$110.14
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-33,844,014.78

Growth

11 metrics
Revenue growth YoY
-58.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$27.82M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,690.7%
Year over year · more shares
Revenue CAGR (3Y)
-1.3%
Revenue CAGR (5Y)
+4.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
345.9%
Return on assets
49.8%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$23.99M
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
-25.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.79M
Total assets
$34.19M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.68M
Capital expenditures (TTM)
—
R&D (TTM)
$25.23M
SG&A (TTM)
—
Stock compensation (TTM)
$577,000
R&D / revenue
90.7%
Stock compensation / revenue
2.1%

Ownership (13F)

3 metrics
13F filers
8
13F filer change QoQ
-3
Institutional ownership
0.1%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1585608 CUSIP 47010C862 13F (30d) 5 filings 5 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)